Bilcare Global Clinical Supplies has enhanced its global Phase III capabilities. The company has upgraded its Kalish large-scale bottling line at its U.S. facility and invested in new Pentapack blistering technology for expanded packaging capabilities in America and Europe.
The Pentapack CT1200L system allows the company to package high-volume runs for large-scale clinical trials and stability tests. This technology provides additional flexibility in trial design and execution to meet individual client needs. The Pentapack system enables the design of blister packaging configurations online using Trialpack Designer II packaging design software, which can be implemented immediately for production. According to the company, the system’s automation significantly reduces manufacturing times and creates a 21 CFR Part 11-compliant electronic paper trail that documents changes from design to production through quality control.
“Bilcare GCS has built its reputation on providing customers with the highest quality research services and clinical supplies delivered on time, every time,” said Vince Santa Maria, president of Bilcare GCS, Americas. “The Pentapack and the expanded Kalish lines are key components to taking Bilcare’s Phase III clinical trial services to the next level by leveraging state-of-the art packaging technologies to deliver superior quality products in a highly flexible and efficient manner. These latest investments are further proof of Bilcare’s long-term commitment to serving the industry with exceptional quality and service beyond compliance.”
Bilcare GCS Expands Phase III Service Capabilities
Published September 9, 2008
blog comments powered by Disqus